$ALZN News

Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro Regains Nasdaq Compliance

Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY

Alzamend Neuro Files Prospectus Related To The Resale Of Up To 98.4M Common Shares By Selling Stockholder

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

Alzamend Neuro Announces Its Abstract On Resting-State Functional Magnetic Resonance Imaging Findings For AL001 Accepted For Presentation At Neuroscience 2026

Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

Alzamend Neuro Signs $25M Securities Purchase Agreement With Ault Lending; Alzamend Receives $7.5M In Gross Proceeds Form Initial Tranche

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

Alzamend Neuro Announces Pharmacodynamic Findings From Brain Magnetic Resonance Spectroscopy Analysis Conducted In Healthy Human Subjects In Trial Conducted At Massachusetts General Hospital

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

Alzamend Announces Topline Data From First Phase II "Lithium In Brain" Clinical Trial, Demonstrating AL001 Meets Bioequivalence Standards, And Showing Numerically Superior Lithium Delivery To Brain Compared To Standard Lithium Carbonate

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Alzamend Neuro Starts Phase II Clinical Study Of AL001 In Participants With Bipolar Disorder Type 1; Topline Data Anticipated By March End

Alzamend Neuro Enters ATM Sales Agreement To Sell Up To $3.0M In Common Stock

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?